REGN vs. WST: Regeneron Pharmaceuticals vs. West Pharmaceutical Services Stock Comparison

Company Profile

Regeneron Pharmaceuticals (REGN) and West Pharmaceutical Services (WST) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but REGN is classified in Biotechnology while WST is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Regeneron Pharmaceuticals (REGN) at 14.95% and West Pharmaceutical Services (WST) at 21.23% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Regeneron Pharmaceuticals (REGN) at 28.51% and West Pharmaceutical Services (WST) at 18.81% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Regeneron Pharmaceuticals (REGN) at 40.46% and West Pharmaceutical Services (WST) at 25.37% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Regeneron Pharmaceuticals (REGN) at 0.99% and West Pharmaceutical Services (WST) at 6.25% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Regeneron Pharmaceuticals (REGN) at 8.19% and West Pharmaceutical Services (WST) at 1.49% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Both Regeneron Pharmaceuticals (REGN) at 3.35 and West Pharmaceutical Services (WST) at 2.82 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Both Regeneron Pharmaceuticals (REGN) at 0.08 and West Pharmaceutical Services (WST) at 0.11 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Both Regeneron Pharmaceuticals (REGN) at 0.41% and West Pharmaceutical Services (WST) at 0.22% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Regeneron Pharmaceuticals (REGN) at 8.18% and West Pharmaceutical Services (WST) at 9.88% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Regeneron Pharmaceuticals (REGN) at 19.99 is near its industry’s usual P/E ratio, while West Pharmaceutical Services (WST) at 44.87 sits in the richer quartile — WST needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Regeneron Pharmaceuticals (REGN) at 5.54 and West Pharmaceutical Services (WST) at 8.20 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Regeneron Pharmaceuticals (REGN) at 2.71 is valued about in line with its industry on P/B ratio, while West Pharmaceutical Services (WST) at 9.40 carries an above-peer premium to book — WST is pricier on assets.

Valuation Metrics